A Next-Generation Sequencing-Based Assay for Hematologic Malignancies
Marcel R.M. van den Brink, MD, PhD, from Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies.
Clinical Pearls
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center, describes a novel CLIA-certified next-generation sequencing-based assay for hematologic malignancies. The analysis of the assay was presented at the 2013 ASH Annual Meeting. Information below reflects that of which was published in the abstract prior to the meeting.
- DNA and RNA were successfully extracted from specimens collected from 319 patients.
- 885 alterations were identified including (but not limited to) mutations inTP53,ASXL1,KRAS,NRAS,IDH2,TET2,SF3B1,JAK2,MLL2,DNMT3A,RUNX1, andSRSF2.
- The test demonstrated a high-level of accuracy at detecting gene substitutions, copy number alterations, insertions, and deletions.
View the full abstract > >
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
